Gene therapies that are based on adeno-associated virus (AAV) vectors have demonstrated immense potential to treat and even cure previously intractable diseases, but unfortunately the costs are ...

Gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. While ...

Novel AEX screening kit – now available for AAV6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple AAV ...

There is no need to waste important AAV samples. Bio-Techne’s automated, high-throughput systems allow the characterization of AAVs in sample volumes as low as 3 µL while maintaining high levels of ...

SPRING HOUSE, Pa. and WATERTOWN, Mass., March 17, 2025 /PRNewswire/ -- ChromaTan Inc., and Landmark Bio PBLLC, today announced they have been awarded a grant from the National Institute for Innovation ...

HOLLISTER, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel ...

VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...

WALTHAM, Mass., Feb. 12, 2025 /PRNewswire/ -- Nanomosaic, a leader in multiplex, multi-omic marker analysis, today announced the publication of a scientific white paper detailing a study conducted ...

VintaBio Presents Data Demonstrating High-Efficiency AAV Vector Production Using Proprietary VintaProcess™ at 2025 ASGCT Annual Meeting The hyper-intensified process delivers significant increases in ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma treatment VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis ...